HONG KONG SAR – Media OutReach Newswire – 2 July 2026 – Natixis Corporate & Investment Banking (Natixis CIB) is pleased to announce the appointment of Luc Bernard as Chief Executive Officer, Natixis Services in India.

Luc reports to Cécile de Sousa, Chief Operating Officer, Asia Pacific & Middle East, Natixis CIB and Etienne Huret, Head of Portugal and India Hubs, Natixis.

He brings to the role nearly two decades of experience in Global Capability Center management and offshoring strategies, entrepreneurship, delivery, software engineering, financial markets, architecture, data, digital transformation and innovation.

Luc was instrumental in establishing Natixis Services in India, Natixis CIB’s technology and innovation hub in Bangalore. He previously held the position of Executive Director and Head of CIB Operations and IT and served on the Board of Directors at Natixis Services in India from 2021 until 2025. He then transitioned to Natixis Investment Managers in Paris, where he has been serving as Head of IT Production until his current appointment. Prior to joining the IT team at Natixis CIB in 2014, Luc gained experience as a Software Developer at Société Générale and Partners Advisers SA. He holds a Master’s degree in Electronic Engineering from Ecole Nationale d’Ingénieurs de Brest and an Executive MBA from HEC Paris.

In his new role as Chief Executive Officer, Luc will support the growth of Natixis Services in India and strengthen its integration within Natixis’s global processes.

Cécile de Sousa said, “It is with great pleasure that we welcome Luc back to Bangalore to lead our India center of expertise as it celebrates its five-year anniversary. He has been pivotal in setting up this crucial operation, and spearheading technology-driven transformation and process optimization. Luc’s extensive knowledge of our internal processes, coupled with his proven track record in India, positions him perfectly to assume the leadership responsibilities of Natixis Services in India.”

Etienne Huret said, “Luc’s appointment is a key milestone in our commitment to further developing Bangalore as a critical hub for the Groupe BPCE and Natixis businesses. I look forward to working with him closely as we continue to grow synergies between our Portugal and India hubs and collaborate closely with the Group on strategic initiatives.”

The issuer is solely responsible for the content of this announcement.

Natixis Corporate & Investment Banking

Natixis Corporate & Investment Banking is a leading global financial institution that provides advisory, investment banking, financing, corporate banking and capital markets services to corporations, financial institutions, financial sponsors and sovereign and supranational organizations worldwide.

Our teams of experts in close to 30 countries advise clients on their strategic development, helping them to grow and transform their businesses, and maximize their positive impact. Natixis CIB is committed to aligning its financing portfolio with a carbon neutrality path by 2050 while helping its clients reduce the environmental impact of their business.

As part of Groupe BPCE, the second largest banking group in France through the Banque Populaire and Caisse d’Epargne retail networks, Natixis CIB benefits from the Group’s financial strength and solid financial ratings (Standard & Poor’s: A+, Moody’s: A2, Fitch Ratings: A+, R&I: A+).

About Natixis Services in India

Natixis Services in India is a Center of Expertise for Groupe BPCE, a banking group of French origin, and its subsidiary, Natixis. Natixis Services in India delivers operational excellence and agile solutions by leveraging advanced technologies to address challenges in the banking industry. Natixis Services in India’s focus is on enhancing the client experience, mitigating risks, and strengthening competitive positioning. The team is committed to enriching career development opportunities within an inclusive and dynamic work environment.

New capability gives enterprises visibility, control and governance for AI tools running across managed Mac fleets, addressing today’s gap between usage and confidence

HONG KONG SAR – Media OutReach Newswire – 2 July 2026 – Jamf, the standard in managing and securing Apple at work, has announced general availability of AI Governance, a new capability within Jamf for Mac that enables IT and security teams to discover actively-used AI tools, enforce policy controls, and generate audit-ready reporting. This move makes Jamf first-to-market to deliver native, OS-level AI governance controls for Mac.

Many organizations struggle to confidently audit and report on AI tool usage across their device fleet, including both sanctioned applications and unsanctioned or prohibited tools. AI Governance provides comprehensive visibility into which AI applications are in use, along with detailed insights into how they behave on the endpoint. This enables organizations to understand AI activity at a level that network- and cloud-based reporting solutions alone cannot provide, helping security teams identify risk, support compliance, and make informed governance decisions.

With launch support for Claude Code, Claude Desktop, and OpenAI Codex, the capability provides deep governance coverage across model access, tenancy, network permissions, file system controls, MCP server restrictions, and other vendor-specific AI configurations. A vendor control tracking engine continuously monitors supported AI platforms for new or updated controls, helping organizations keep governance policies current as AI tools rapidly evolve. All of these policies are in place offline and before a user’s first login to an AI agent, enforcing a foundational day-zero and tamper-resistant policy baseline.

The only native Mac control plane for enterprise AI

AI tools run natively on Apple Silicon and operate as processes that existing network proxies and cloud-based tooling cannot fully see or govern. No existing tool unifies platform-native device management, deep AI tool configuration coverage, and a workflow that translates governance intent into vendor-correct configuration on macOS.

Jamf AI Governance closes that gap by enabling visibility of Shadow AI and providing granular AI configurations natively, deployed in minutes, through the same endpoint management control plane that admins use today, offering:

• Visibility: AI application visibility and shadow AI discovery surface AI tools, agents, and LLM runtime across the fleet (including CLI-based developer tools and background agents) using Jamf’s existing telemetry agent, which uses native and high-performance macOS frameworks. No new agent is required.
• Control: AI access policy controls let IT define sanctioned tools, deploy access policy at scale, and scope different postures to different teams. Vendor-correct configurations can be applied automatically at scale.
• Governance: An executive AI posture report provides CIOs and CISOs with a snapshot-in-time summary of AI usage. The capability offers SIEM compatibility and is designed to assist companies in reporting against their existing compliance frameworks.

“AI adoption across the enterprise is moving faster than existing technology policies can keep up,” said Beth Tschida, CEO at Jamf. “Organizations need governance that matches the way AI tools actually operate on Mac. This means visibility into what’s running, policy controls enforced directly on the endpoint, and reporting that helps security teams demonstrate compliance. Our AI Governance capability delivers that natively from the same platform customers already trust to manage and secure Apple devices.”

“Like many organizations, we want to enable teams to use AI tools productively while maintaining appropriate governance and oversight,” said Sam Lalli, Security Engineering & SOC Manager at Eventbrite “What impressed us about Jamf’s AI Governance was how quickly we could apply policy across our Mac fleet without adding another point solution or creating friction for developers. Having this critical capability built into the same device management platform we already use, really simplifies AI governance for our team.”

Jamf enables partner AI solutions to thrive on the Mac

Beyond essential visibility and control, Jamf’s AI Governance policies can more effectively deploy and govern partner AI solutions.

IT and security teams can use Jamf to discover AI tools running across MacOS devices and register those agents directly with Okta for AI Agents. This gives each one a managed identity and scoped access to only the resources it is allowed to reach. Jamf controls which MCP servers can run on the device while Okta controls what cloud resources those MCP servers can reach. Rather than long-lived static keys, agents use short-lived, vaulted credentials, and every action is authorized and logged from the endpoint to the cloud. The Okta integration deploys directly from Jamf’s console without manual API setup or certificate management required.

Organizations can also configure their preferred agent builder platform, such as Amazon Bedrock AgentCore, ensuring AI traffic routes through and is processed on sanctioned cloud infrastructure.

With Jamf handling device visibility and policy enforcement, and Okta managing agent identity and access, organizations can answer: which agents ran on which endpoints, what they were authorized to reach, and what they did along the path from a MacOS device to the SaaS app.

“While some enterprise AI agents run locally, they access data across a vast cloud ecosystem, requiring coordinated security between the endpoint and identity layers,” said Harish Peri, SVP & GM of AI Security, Okta. “By anchoring Okta for AI Agents to Jamf’s endpoint enforcement, every agentic connection on a managed Mac is authenticated, authorized, and fully visible from the device to the data. Together, we’re helping organizations become secure agentic enterprises by giving them more control over what AI agents can access and on whose behalf.”

AI governance urgency is accelerating

The need for enterprise AI governance is accelerating as organizations rapidly adopt AI-powered tools across employee workflows. Jamf’s recently released AI Governance Survey found that organizations with deeply integrated AI are 40% more likely to report an incident than those still in the exploration phase, suggesting AI governance is quickly becoming an operational requirement rather than a future planning exercise.

Gartner® mentions, “With spending on AI governance expected to reach $492 million in 2026 and surpass $1 billion by 2030, organizations are reassessing the tools and strategies needed to stay ahead of both regulatory and operational risk.” Further, in its Top Cybersecurity Trends for 2026 report, Gartner also says that, “Cybersecurity leaders must identify both sanctioned and unsanctioned AI agents, enforce robust controls for each and develop incident response playbooks to address potential risks.”

Jamf’s AI Governance capability is now available in Jamf for Mac with immediate support for Claude Code, Claude Desktop, and OpenAI Codex. Learn more about Jamf AI Governance at: https://www.jamf.com/solutions/ai-governance

Hashtag: #software #apple #Jamf

The issuer is solely responsible for the content of this announcement.

About Jamf

Jamf’s purpose is to simplify work by helping organizations manage and secure Apple devices while delivering an experience end users love and organizations trust. Built for the AI-enabled Apple enterprise, the Jamf platform provides a complete management and security solution with autonomous endpoint management and AI governance across cloud and on-device models. Today, Jamf helps over 78,000 organizations across 100 countries manage and secure over 35 million devices. To learn more, visit www.jamf.com.

Appointment reinforces the hospital’s commitment to clinical excellence, strategic growth and delivering exceptional patient care.

KOTA DAMANSARA, MALAYSIA – Media OutReach Newswire – 2 July 2026 – Thomson Hospital Kota Damansara (Thomson) is pleased to announce the appointment of Dr Savitha Dharan as its Chief Executive Officer, effective 1 July 2026.

Dr Savitha brings more than 20 years of experience in clinical practice, hospital operations, strategic partnerships, business development and healthcare leadership. She holds a Bachelor of Medicine, Bachelor of Surgery and Bachelor in the Art of Obstetrics (MB BCh BAO) from the Royal College of Surgeons in Ireland (RCSI) and completed executive education in Managing Health Care Delivery at Harvard Business School.

Following a decade in clinical practice across the public and private sectors, Dr Savitha progressed into healthcare leadership, holding senior roles within recognised private healthcare groups and institutions. As a Chief Executive Officer, she has successfully led business transformation, operational excellence, service innovation and strategic growth initiatives.

Welcoming the appointment, Dato’ Dr. Adzuan Rahman, Group Chief Executive Officer of TMC Life Sciences Berhad, said:

“We are delighted to welcome Dr Savitha to the TMC Life Sciences family. Her strong clinical foundation, proven leadership and strategic vision make her the right leader to guide Thomson Hospital Kota Damansara into its next phase of growth. We are confident she will further strengthen the hospital’s position as a leading multidisciplinary tertiary healthcare provider while advancing our commitment to clinical excellence, innovation and value-driven care.”

Dr Savitha’s appointment underscores Thomson’s commitment to clinician-led leadership, recognising that strong clinical expertise, coupled with sound management capabilities, forms the foundation of patient-centred decision-making and the delivery of high-quality healthcare.

Commenting on her appointment, Dr Savitha stated, “It is a privilege to lead Thomson Hospital Kota Damansara, an organisation with a strong reputation for delivering exceptional patient care. As both a clinician and a healthcare leader, I believe the best outcomes are achieved by empowering our people, embracing innovation, and continuously improving patient experience. I look forward to working alongside our dedicated teams to build on the hospital’s strong foundation and shape its next chapter of excellence.”

Hashtag: #ThomsonHospital

The issuer is solely responsible for the content of this announcement.

About Thomson Hospital Kota Damansara

Established in 2008, Thomson Hospital Kota Damansara (THKD) is the flagship hospital of TMC Life Sciences Berhad (TMCLS) located in a prime alcove of Kota Damansara, Selangor. THKD is expected to grow to a 554-bedded hospital with additional specialist centres and operating theatres as part of the Group’s expansion plan. THKD sets new standards in healthcare through comprehensive facilities and excellent service for both our local and international patients. The Hospital offers medical and surgical services from over 160 reputable specialist consultants covering more than 60 medical and surgical sub-specialties.

For more information, please visit thomsonhospitals.com or follow THKD on social media platforms @thomsonhospitalKD.

HONG KONG SAR – EQS Newswire – 2 July 2026 – On June 30, 2026, Guangdong TrueHealth Medical Technology Development Co., Limited (referred to as “TrueHealth Medical” or the “Company”, stock code: 02697.HK) has made its debut on the Main Board of the Hong Kong Stock Exchange, becoming the first HKEX-listed specialist in percutaneous surgical robotics. At market close, the Company’s stock settled at HK$400.0, representing an increase of HK$273.8 from its IPO offer price of HK$126.2, marking a 216.96% surge on its trading debut. Total trading volume hit HK$320 million, and the Company’s total market capitalization stood at HK$14.259 billion based on the closing price.

TrueHealth Medical drew heavy investor attention on its trading debut, building on robust pre-listing gray market sentiment. Ahead of the IPO, Futu Securities’ gray market sessions saw the stock hit a peak of HK$358, representing a 183.7% premium to the offer price. The upbeat market sentiment underscores strong investor appetite for the underserved niche segment of percutaneous puncture and ablation surgical robots.

Founded in 2018 as outlined in its prospectus, TrueHealth Medical specializes in the research, development and commercialization of percutaneous puncture and ablation robotic systems in China. Its flagship percutaneous surgical robot lineup comprises four variants: TH-S1, TH-S, TH-S Pro and TH-SA. All four hold Class III medical device registrations issued by the National Medical Products Administration (NMPA), cleared for navigation and positioning during percutaneous procedures on solid abdominal and pulmonary organs in adult patients. The TH-S model has received NMPA accreditation as a China-first innovation.

Beyond its core systems, the Company’s pipeline extends to percutaneous microwave ablation robotics. Its flagship TH-X MW system, approved for liver and lung tumor treatment, has secured NMPA recognition as a world-first innovation, while the TH-X HMW system is cleared solely for liver tumor interventions. The Company holds a full-spectrum product matrix spanning puncture navigation and positioning, microwave ablation therapy and pipeline candidates.

On industry leadership, research from CIC Consulting ranks TrueHealth Medical as China’s market leader by both shipment volume and revenue for percutaneous surgical robots in 2025, commanding respective market shares of 36.4% by shipment volume and 28.0% by revenue. As of the latest practicable date, 21 percutaneous surgical robotic systems have won NMPA approval nationwide, five of which belong to TrueHealth Medical – making the Company the earliest and most prolific developer of cleared devices in this specialized segment.

On commercialization, TrueHealth Medical booked annual revenues of RMB1.791 million in 2024 and RMB12.178 million in 2025. A total of six robotic systems were delivered throughout 2025, including two TH-S, one TH-P, one TH-S Pro and two TH-X MW. With an expanding roster of approved systems, broadening clinical adoption and maturing sales networks, the Company stands at a pivotal transition from product validation to scaled commercial growth.

Its Hong Kong listing equips TrueHealth Medical with capital markets backing to accelerate commercialization of core hardware, advance R&D for existing and pipeline systems, and scale manufacturing and go-to-market capabilities. The Company will continue building an intelligent robotics portfolio centered on percutaneous positioning and precision therapy, delivering cutting-edge minimally invasive solutions for oncology diagnosis and treatment.

Speaking at the listing ceremony, Cheong Hou Iam, the chairperson, executive director and general manager, commented: “TrueHealth Medical stays committed to resolving unmet clinical pain points via technological innovation. We focus on the R&D and commercialization of percutaneous puncture and ablation robotics. Drawing on deep technical expertise and extensive clinical validation, we iterate our products and broaden our offerings to build a robust moat in precision minimally invasive treatment. Surgical robotics is now entering a golden era, boosted by vast market prospects. Leveraging our first-mover advantage and industrial resources, we will capitalize on industry tailwinds, unlock full value and deliver sustainable returns to all our shareholders and investors.”

Hashtag: #TrueHealthMedical

The issuer is solely responsible for the content of this announcement.

About TrueHealth Medical Technology Development Co., Limited

A nationally accredited “Little Giant” enterprise (Specialized, Sophisticated, Distinctive & Innovative), Guangdong TrueHealth Medical Technology Development Co., Limited leverages artificial intelligence and robotic control technologies to develop and commercialize intelligent robots for soft tissue puncture diagnosis and organ repair. Its core offerings cover percutaneous puncture navigation and microwave ablation guided systems. The ZhenYiDa® percutaneous puncture navigation and positioning system holds NMPA China-first certification, while the ZhenYiDa® navigation and positioning microwave ablation system is accredited as a world-first innovation by NMPA. The Company undertakes key projects under China’s 14th Five-Year National Key R&D Program, with its products featured in national flagship schemes including high-end medical device roll-out initiatives, AI medical device innovation program and the Catalog of Outstanding Domestic Medical Devices. TrueHealth Medical aims to deploy AI and surgical robotics to advance precision, minimally invasive therapeutic solutions for widespread clinical use.